Carfilzomib: A cause of drug associated thrombotic microangiopathy

Ibrahim Qaqish; Ilana M. Schlam; Harini A. Chakkera; Rafael Fonseca; Jill Adamski

doi:10.1016/j.transci.2016.03.002

Carfilzomib: A cause of drug associated thrombotic microangiopathy

Ibrahim Qaqish, Ilana M. Schlam, Harini A. Chakkera, Rafael Fonseca, Jill Adamski

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Carfilzomib is a selective proteosome inhibitor approved for treatment of relapsed and refractory multiple myeloma. Recent reports have linked exposure to carfilzomib with development of thrombotic microangiopathy (TMA). We describe two cases of biopsy proven thrombotic microangiopathy that occurred after the initiation of carfilzomib (dosed at 32 mg/m² and 23 mg/m², respectively) for relapsed multiple myeloma. Both patients were managed with discontinuation of the drug, therapeutic plasma exchange (TPE) and supportive care. Hemoglobin, platelets and renal function did not improve with TPE. TMA resolved with creatinine returning to baseline several weeks after discontinuation of the drug. The outcomes suggest that TPE is not beneficial for treating carfilzomib-induced TMA.

Original language	English (US)
Pages (from-to)	401-404
Number of pages	4
Journal	Transfusion and Apheresis Science
Volume	54
Issue number	3
DOIs	https://doi.org/10.1016/j.transci.2016.03.002
State	Published - Jun 1 2016

Keywords

Apheresis
Therapeutic plasma exchange
Thrombotic microangiopathy

ASJC Scopus subject areas

Hematology

Access to Document

10.1016/j.transci.2016.03.002

Cite this

@article{1a1ac80508684fa7bc8ace529e9cbd6c,

title = "Carfilzomib: A cause of drug associated thrombotic microangiopathy",

abstract = "Carfilzomib is a selective proteosome inhibitor approved for treatment of relapsed and refractory multiple myeloma. Recent reports have linked exposure to carfilzomib with development of thrombotic microangiopathy (TMA). We describe two cases of biopsy proven thrombotic microangiopathy that occurred after the initiation of carfilzomib (dosed at 32 mg/m2 and 23 mg/m2, respectively) for relapsed multiple myeloma. Both patients were managed with discontinuation of the drug, therapeutic plasma exchange (TPE) and supportive care. Hemoglobin, platelets and renal function did not improve with TPE. TMA resolved with creatinine returning to baseline several weeks after discontinuation of the drug. The outcomes suggest that TPE is not beneficial for treating carfilzomib-induced TMA.",

keywords = "Apheresis, Therapeutic plasma exchange, Thrombotic microangiopathy",

author = "Ibrahim Qaqish and Schlam, {Ilana M.} and Chakkera, {Harini A.} and Rafael Fonseca and Jill Adamski",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Ltd.",

year = "2016",

month = jun,

day = "1",

doi = "10.1016/j.transci.2016.03.002",

language = "English (US)",

volume = "54",

pages = "401--404",

journal = "Transfusion and Apheresis Science",

issn = "1473-0502",

publisher = "Elsevier Limited",

number = "3",

}

TY - JOUR

T1 - Carfilzomib

T2 - A cause of drug associated thrombotic microangiopathy

AU - Qaqish, Ibrahim

AU - Schlam, Ilana M.

AU - Chakkera, Harini A.

AU - Fonseca, Rafael

AU - Adamski, Jill

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Carfilzomib is a selective proteosome inhibitor approved for treatment of relapsed and refractory multiple myeloma. Recent reports have linked exposure to carfilzomib with development of thrombotic microangiopathy (TMA). We describe two cases of biopsy proven thrombotic microangiopathy that occurred after the initiation of carfilzomib (dosed at 32 mg/m2 and 23 mg/m2, respectively) for relapsed multiple myeloma. Both patients were managed with discontinuation of the drug, therapeutic plasma exchange (TPE) and supportive care. Hemoglobin, platelets and renal function did not improve with TPE. TMA resolved with creatinine returning to baseline several weeks after discontinuation of the drug. The outcomes suggest that TPE is not beneficial for treating carfilzomib-induced TMA.

AB - Carfilzomib is a selective proteosome inhibitor approved for treatment of relapsed and refractory multiple myeloma. Recent reports have linked exposure to carfilzomib with development of thrombotic microangiopathy (TMA). We describe two cases of biopsy proven thrombotic microangiopathy that occurred after the initiation of carfilzomib (dosed at 32 mg/m2 and 23 mg/m2, respectively) for relapsed multiple myeloma. Both patients were managed with discontinuation of the drug, therapeutic plasma exchange (TPE) and supportive care. Hemoglobin, platelets and renal function did not improve with TPE. TMA resolved with creatinine returning to baseline several weeks after discontinuation of the drug. The outcomes suggest that TPE is not beneficial for treating carfilzomib-induced TMA.

KW - Apheresis

KW - Therapeutic plasma exchange

KW - Thrombotic microangiopathy

UR - http://www.scopus.com/inward/record.url?scp=84962530615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962530615&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2016.03.002

DO - 10.1016/j.transci.2016.03.002

M3 - Article

C2 - 27017313

AN - SCOPUS:84962530615

SN - 1473-0502

VL - 54

SP - 401

EP - 404

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

IS - 3

ER -

Carfilzomib: A cause of drug associated thrombotic microangiopathy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this